Evidence map›Paper›PMID 33548393›Full record

ArticleJournal of microbiological methods2021

A rapid, antibiotic susceptibility test for multidrug-resistant, Gram-negative bacterial uropathogens using the biochemical assay, DETECT.

Nicole Jackson, Clarissa A Borges, Nicole J Tarlton, Angel Resendez, Aubrianne K Milton, Tara R de Boer, Cheyenne R Butcher, Niren Murthy, Lee W Riley

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of microbiological methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Use ofAntibiotics (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Nicole JacksonSchool of Public Health, Department of Infectious Diseases and Vaccinology, University of California Berkeley, Berkeley, CA, USA. Electronic address: nicolejackson@berkeley.edu.
Clarissa A BorgesSchool of Public Health, Department of Infectious Diseases and Vaccinology, University of California Berkeley, Berkeley, CA, USA.
Nicole J TarltonDepartment of Microbiology, BioAmp Diagnostics, Inc., San Carlos, CA, USA.
Angel ResendezDepartment of Chemistry, BioAmp Diagnostics, Inc., San Carlos, CA, USA.
Aubrianne K MiltonDepartment of Chemistry, BioAmp Diagnostics, Inc., San Carlos, CA, USA.
Tara R de BoerDepartment of Chemistry, BioAmp Diagnostics, Inc., San Carlos, CA, USA.
Cheyenne R ButcherSchool of Public Health, Department of Infectious Diseases and Vaccinology, University of California Berkeley, Berkeley, CA, USA.
Niren MurthyDepartment of Bioengineering, University of California Berkeley, Berkeley, CA, USA.
Lee W RileySchool of Public Health, Department of Infectious Diseases and Vaccinology, University of California Berkeley, Berkeley, CA, USA. Electronic address: lwriley@berkeley.edu.
University of California, Berkeley · US

Funding

Consortium for drug-resistant Gram-negative pathogen detectionR01AI117064 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LEE, LUKE P., MURTHY, NIREN · 2015 to 2019
$5.7M
NIAID NIH HHS R01 AI117064
6 · The paper itself

Abstract

The increasing prevalence of extended spectrum β-lactamases (ESBLs) and plasmid-mediated AmpC (pAmpC) β-lactamases among Enterobacterales threatens our ability to treat urinary tract infections (UTIs). These organisms are resistant to most β-lactam antibiotics and are frequently multidrug-resistant (MDR). Consequently, they are often resistant to antibiotics used to empirically treat UTIs. The lack of rapid diagnostic and antibiotic susceptibility tests (AST) makes clinical management of UTIs caused by such organisms difficult, as standard culture and susceptibility assays require several days. We have adapted a biochemical detection assay, termed dual-enzyme trigger-enabled cascade technology (DETECT) for rapid detection of resistance (time-to-result of 3 h) to other antibiotics commonly used in treatment of UTIs. DETECT is activated by the presence of CTX-M and pAmpC β-lactamases. In this proof-of-concept study, the adapted DETECT assay (AST-DETECT) has been performed on pure-cultures of Klebsiella pneumoniae and Escherichia coli (48 isolates) expressing ESBL or pAmpC β-lactamases to perform AST for ciprofloxacin (sensitivity 96.9%, specificity 100%, accuracy 97.9%) nitrofurantoin (sensitivity 95.7%, specificity 91.7%, accuracy 94%) and trimethoprim/sulfamethoxazole (sensitivity 83.3%, specificity 100%, accuracy 89.4%). These results suggest that AST-DETECT may be adapted as a potential diagnostic platform to rapidly detect multidrug-resistant E. coli and K. pneumoniae that cause UTI.

Indexed as

Drug Resistance, Multiple, BacterialEscherichia coliKlebsiella pneumoniaeBacterial Proteinsbeta-LactamasesEscherichia coli InfectionsHumansKlebsiella InfectionsProof of Concept StudyUrinary Tract InfectionsAmpC beta-lactamasesBacterial Proteinsbeta-LactamasesAntibiotic resistanceAntimicrobial susceptibility testingExtended-spectrum β-lactamaseInfectious disease diagnosticsUrinary tract infection

Identifiers

PMID33548393
PMCPMC7925429
OpenAlexW3128864263

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.